scispace - formally typeset
R

Raphaële Renard-Penna

Researcher at Pierre-and-Marie-Curie University

Publications -  79
Citations -  2167

Raphaële Renard-Penna is an academic researcher from Pierre-and-Marie-Curie University. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 23, co-authored 48 publications receiving 1851 citations.

Papers
More filters
Journal ArticleDOI

A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma

TL;DR: A meta-analysis of available data identified significant predictors of IVR that should be systematically assessed to propose a risk-adapted approach to adjuvant intravesical instillation of chemotherapy and cystoscopic surveillance after RNU.
Journal ArticleDOI

Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations—A Report of a European School of Oncology Task Force

TL;DR: PRECISE recommendations are designed to facilitate the development of a robust evidence database for documenting changes in prostate MRI findings over time of men on active surveillance and to distinguish measurement error and natural variability in MRI appearances from true radiologic progression.
Journal ArticleDOI

Long-Term Outcomes After Nephron Sparing Surgery for Renal Cell Carcinoma Larger Than 4 cm

TL;DR: The results support the fact that nephron sparing surgery is a useful and acceptable approach to renal cell carcinoma greater than 4 cm and when technically possible, nephrons sparing surgery provides acceptable long-term cancer specific survival rates.
Journal ArticleDOI

First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer.

TL;DR: To assess the accuracy of magnetic resonance imaging (MRI)/transrectal ultrasonography (TRUS) fusion to guide first‐round biopsies in the diagnosis of localised prostate cancer (PCa) in men with a prostate‐specific antigen (PSA) ≤10 ng/mL, MRI/TRUS fusion is used.